HealthCor Management’s Syndax Pharmaceuticals SNDX Stock Holding History

HealthCor Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.78M	Sell	70,000 -789,240	-92%	-$18.4M	1.63%	9
2022 Q3	$20.6M	Sell	859,240 -64,160	-7%	-$1.44M	2.58%	15
2022 Q2	$17.8M	Sell	923,400 -257,100	-22%	-$4.28M	1.79%	26
2022 Q1	$20.5M	Buy	1,180,500 +22,940	+2%	+$386K	1.37%	32
2021 Q4	$25.3M	Sell	1,157,560 -57,110	-5%	-$1.06M	1.38%	27
2021 Q3	$23.2M	Sell	1,214,670 -536,672	-31%	-$8.94M	1%	29
2021 Q2	$30.1M	Buy	1,751,342 +379,862	+28%	+$6.96M	1.2%	31
2021 Q1	$30.7M	Buy	1,371,480 +300,930	+28%	+$6.8M	1.09%	34
2020 Q4	$23.8M	Buy	1,070,550 +1,038,350	+3,225%	+$21.5M	0.92%	35
2020 Q3	$475K	Buy	+32,200	New	+$491K	0.02%	40

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

HealthCor Management's SNDX Position: Q4 2022 in Review

HealthCor Management reduced its Syndax Pharmaceuticals (SNDX) stake by 92% in Q4 2022, selling an estimated $18.4M and leaving 70,000 shares worth $1.78M. The position accounts for 1.63% of the portfolio, ranked #9.

HealthCor Management first reported a position in SNDX in Q3 2020 and has held it in 10 quarters since. The position peaked at $30.7M in Q1 2021. 160 funds tracked by Wall St. Rank hold SNDX as of Q4 2022.

HealthCor Management held 70,000 shares of Syndax Pharmaceuticals worth $1.78M as of Q4 2022.
HealthCor Management sold 789,240 Syndax Pharmaceuticals shares in Q4 2022, an estimated $18.4M.
Syndax Pharmaceuticals made up 1.63% of HealthCor Management's portfolio in Q4 2022, its #9 holding.
HealthCor Management first reported a position in Syndax Pharmaceuticals in Q3 2020 and has held it in 10 quarters since.
HealthCor Management's Syndax Pharmaceuticals position peaked at $30.7M in Q1 2021.
160 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2022.

Based on HealthCor Management's 13F filing for Q4 2022, filed 15 Feb 2023.